SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Adam R, McMaster P, O'Grady JG, Castaing D, Klempnauer JL, Jamieson N, et al.; for European Liver Transplant Association. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003; 9: 12311243.
  • 2
    2009 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1999-2008. http://www.srtr.org/annual_reports/2010/ar_archives. htm. Accessed July 2012.
  • 3
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889896.
  • 4
    Selzner N, Renner EL, Selzner M, Adeyi O, Kashfi A, Therapondos G, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 2009; 88: 12141221.
  • 5
    Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459465.
  • 6
    Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274287.
  • 7
    Fernández I, Meneu JC, Colina F, García I, Muñoz R, Castellano G, et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006; 12: 18051812.
  • 8
    Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 12821288.
  • 9
    Goto K, Watashi K, Murata T, Hishiki T, Hijikata M, Shimotohno K. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem Biophys Res Commun 2006; 343: 879884.
  • 10
    Liu JP, Ye L, Wang X, Li JL, Ho WZ. Cyclosporin A inhibits hepatitis C virus replication and restores interferon-alpha expression in hepatocytes. Transpl Infect Dis 2011; 13: 2432.
  • 11
    ReViS-TC Study Group. Cyclosporine A-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study. Transplantation 2011; 92: 334340.
  • 12
    Cescon M, Grazi GL, Cucchetti A, Vetrone G, Ravaioli M, Ercolani G, et al. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl 2009; 15: 782789.
  • 13
    Truven Health Analytics. Micromedex 2.0. http://www.micromedex.com/index.html. Accessed July 2012.
  • 14
    Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_ epidemiology/oxford.htm. Accessed July 2012.
  • 15
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557560.
  • 16
    Calmus Y, Samuel D, Pageaux G, Messner M, Wolf P, Rostaing L, et al. Multicenter randomized trial in HCV-infected patients treated with peginterferon alfa-2a and ribavirin followed by ribavirin alone after liver transplantation: 18-month report [abstract]. Hepatology 2006; 44( suppl 1): 189A.
  • 17
    Carrión JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 17461756.
  • 18
    Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila-Pico C, Machicao VI, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006; 12: 5157.
  • 19
    Firpi RJ, Soldevila-Pico C, Morelli GG, Cabrera R, Levy C, Clark VC, et al. The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig Dis Sci 2010; 55: 196203.
  • 20
    Gordon FD, Poordad F, Neff GW, Mukherjee S, Barnard G, Barnes DS, et al. Baseline, donor, and on-treatment predictors of sustained virologic response in patients treated for recurrent hepatitis C following orthotopic liver transplant: subanalysis of the PROTECT study [abstract]. Hepatology 2010; 52( suppl 1): 754A.
  • 21
    Ikegami T, Taketomi A, Soejima Y, Yoshizumi T, Fukuhara T, Kotoh K, et al. The benefits of interferon treatment in patients without sustained viral response after living donor liver transplantation for hepatitis C. Transplant Proc 2009; 41: 42464252.
  • 22
    Jiménez-Pérez M, Sáez-Gómez AB, Pérez-Daga JA, Lozano-Rey JM, de la Cruz-Lombardo J, Rodrigo-López JM. Hepatitis C virus recurrence after liver transplantation: analysis of factors related to sustained viral response. Transplant Proc 2010; 42: 666668.
  • 23
    Lodato F, Berardi S, Gramenzi A, Mazzella G, Lenzi M, Morelli MC, et al. Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation. Aliment Pharmacol Ther 2008; 28: 450457.
  • 24
    Oton E, Barcena R, Moreno-Planas JM, Cuervas-Mons V, Moreno-Zamora A, Barrios C, et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006; 6: 23482355.
  • 25
    Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008; 14: 17661777.
  • 26
    Vero V, Senzolo M, Pasulo L, Ponziani F, Raffaella V, Marino M et al. Is the primary immunosuppressive drug (cyclosporine or tacrolimus) playing a role on the response to antiviral treatment for post-transplant HCV recurrence [abstract]? Liver Transpl 2011; 17( suppl 1): S97.
  • 27
    Giusto M, Rodriguez M, Navarro L, Rubin A, Aguilera V, San-Juan F, et al. Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin. Liver Transpl 2011; 17: 13181327.
  • 28
    Bitetto D, Falleti E, Fornasiere E, Belli L, Vigano R, Fagiuoli S et al. Interaction between cyclosporine and recipient IL-28B RS12979860 C>T genetic polymorphisms in the achievement of sustained viral response for recurrent hepatitis C [abstract]. J Hepatol 2012; 56( suppl 2): S37.
  • 29
    Ishii N, Watashi K, Hishiki T, Goto K, Inoue D, Hijikata M, et al. Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol 2006; 80: 45104520.
  • 30
    Hirano K, Ichikawa T, Nakao K, Matsumoto A, Miyaaki H, Shibata H, et al. Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin A, on interferon-induced antiviral protein in human hepatocyte cells. Liver Transpl 2008; 14: 292298.
  • 31
    Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, Shimotohno K. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005; 19: 111122.
  • 32
    Watashi K, Shimotohno K. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy. Rev Med Virol 2007; 17: 245252.
  • 33
    Hurtova M, Fourti M, Medjahed N, Samuel D, Neau-Cransac M, Calmus Y, et al. Early virological response and absence of diabetes are associated with sustained virological response to hepatitis C treatment after liver transplantation in patients with cyclosporine A based immunosuppression [abstract]. Hepatology 2008; 48( suppl 1): 581A.
  • 34
    Levy G, Villamil F, Samuel D, Sanjuan F, Grazi GL, Wu Y, et al.; for LIS2T Study Group. Results of LIS2T, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004; 77: 16321638.
  • 35
    Kawaoka T, Takahashi S, Takaki S, Hiramatsu A, Waki K, Hiraga N, et al. IL28B SNP of donors and recipients can predict virological response to PEGIFN/RBV therapy in patients with recurrent hepatitis C after living donor liver transplantation. J Gastroenterol Hepatol; doi:10.1111/j.1440-1746.2012.07129.x.
  • 36
    Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120129.e18.
  • 37
    Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 2027.
  • 38
    Hulskotte E, Gupta S, Xuan F, van Zutven M, O'Mara E, Feng HP, et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology; doi:10.1002/hep.25831.
  • 39
    Irish WD, Arcona S, Bowers D, Trotter JF. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant 2011; 11: 16761685.